Valuation: Novacyt

Market Cap 29.6M 33.85M 27.18M 25.36M 48.05M 3.22B 48.76M 327M 127M 1.58B 127M 124M 5.46B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 31.56M 36.08M 28.98M 27.03M 51.23M 3.44B 51.98M 348M 135M 1.69B 135M 133M 5.82B EV / Sales 2026 *
1.03x
EV / Sales 2027 * 0.99x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+2.00%
1 week+1.87%
Current month+3.55%
1 month-14.00%
3 months+9.66%
6 months-2.74%
Current year+4.48%
1 week 0.38
Extreme 0.3805
0.41
1 month 0.38
Extreme 0.3765
0.52
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap.
Mar. 29Buy

Chief Executive Officer

1,792 0.0025%
Mar. 29Buy

Chief Executive Officer

56,438 0.0799%
Mar. 29Buy

Chairman

15,228 0.0216%
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%+1.87%-16.38%-3.61% 33.21M
+1.28%+3.67%-36.60%-40.24% 588M
+2.96%+0.12%+166.29% - 400M
+0.58%+4.52%+72.64%+126.80% 135M
+3.03%+3.79%-32.45%+15.11% 122M
Average +1.97%-3.31%+30.70%+24.51% 255.48M
Weighted average by Cap. +1.92%-4.82%+39.30%-5.58%

Financials

2026 *2027 *
Net sales 30.52M 34.9M 28.03M 26.15M 49.55M 3.32B 50.28M 337M 131M 1.63B 131M 128M 5.63B 34.86M 39.86M 32.01M 29.86M 56.59M 3.8B 57.43M 385M 149M 1.87B 150M 146M 6.43B
Net income - -
Net Debt 1.96M 2.24M 1.8M 1.68M 3.18M 213M 3.22M 21.59M 8.39M 105M 8.4M 8.21M 361M 4.84M 5.54M 4.45M 4.15M 7.86M 527M 7.98M 53.45M 20.76M 259M 20.79M 20.33M 894M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-07-03 €0.4085 +2.00% 80,162
26-07-02 €0.4005 -1.48% 97,800
26-07-01 €0.4065 +3.04% 252,090
26-06-30 €0.3945 +2.20% 122,323
26-06-29 €0.3860 -2.77% 197,386

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock